Semaglutide is now well known as the active ingredient in Novo Nordisks blockbuster type 2 diabetes drug Ozempic and weight-loss drug Wegovy, which were approved by the US Food and Drug Administration in 2017 and 2021, respectively

Mutations of the tumor suppressor gene TP53 represent a common mutation in myeloid malignancies, occurring in 10-20% of patients with de novo myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with profound negative impact on outcomes and a median overall survival (OS) of 6-12 months.31 Critically, the clonal burden of TP53 , that is the variant allele frequency (VAF) and/or allelic state of TP53 , is intimately tied with the clinical trajectory of these patients and is a robust, independent predictor of survival.74 Given the poor OS and lack of therapeutic options for TP53 mutant MDS/AML patients, a number of novel agents are being investigated in this patient group.8 Of these, APR-246 has evoked considerable excitement based on its robust clinical efficacy in combination with azacitidine in TP53 mutant MDS/AML patients.109 In this issue of Haematologica ,11 Maslah et al

2.15 Protein crystallography Crystallization trials were set up at room temperature with a Crystal Gryphon crystallization robot (Art Robbins Instruments) in Intelli 963 plates (Art Robbins Instruments) with 200 nL protein solution at a concentration of 40 mg/mL supplemented with 7 mM D-malate and 200 nL reservoir solution
Co daje L-karnityna
Basically, glucagon-like peptide-1 (GLP-1) improves glycemic control in diabetic patients and improves heart and kidney health